Maze Therapeutics’ (MAZE) “Buy” Rating Reiterated at BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a note issued to investors on Monday,Benzinga reports. They currently have a $46.00 price target on the stock. BTIG Research’s target price points to a potential upside of 2.61% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Guggenheim boosted their price target on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.57.

Maze Therapeutics Trading Down 1.0%

NASDAQ MAZE opened at $44.83 on Monday. The stock has a market cap of $2.16 billion, a PE ratio of -2.14 and a beta of 4.47. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $49.25. The company’s 50-day moving average price is $43.91 and its 200-day moving average price is $34.63.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total transaction of $332,025.00. Following the transaction, the insider directly owned 10,503 shares in the company, valued at approximately $464,967.81. This trade represents a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $596,908.60. This trade represents a 27.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 200,000 shares of company stock valued at $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the fourth quarter valued at about $39,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $43,000. Finally, Russell Investments Group Ltd. grew its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.